MAPK3 and lung adenocarcinoma: In an article by Hrustanovic et al., the authors reported that DUSP6 KD promoted resistance to ALK inhibitors in vitro as well as in individuals with EML4- and ALK-positive lung adenocarcinoma by reactivation of ERK1/2 signalling [153].